Binding to carboxypeptidase M mediates protective effects of fibrinopeptide Bβ15-42

Transl Res. 2019 Nov:213:124-135. doi: 10.1016/j.trsl.2019.07.008. Epub 2019 Jul 26.

Abstract

During fibrinolysis a 28-amino-acid peptide is generated besides other degradation products of fibrin. This peptide, called Bβ15-42, which is cleaved by plasmin from the end of the fibrin Bβ-chain, is protective in myocardial and renal ischemia/reperfusion injury and improves the outcome in experimental sepsis. Bβ15-42 has been shown to mediate different beneficial effects in endothelial cells through binding to vascular endothelial-cadherin. Here, we provide in vitro and in vivo evidence that Bβ15-42 has additional cell protective activity in tubular cells, which is caused by a distinct mechanism. As vascular endothelial-cadherin is not expressed by tubular cells we used ligand-receptor capture technology LRC-TriCEPS to search for tubular cell surface receptors and identified carboxypeptidase M (CBPM) as a novel binding partner of Bβ15-42. Silencing CBPM with siRNA reduced the protective potential of Bβ15-42 against tubular cell stress. Bβ15-42 inhibited the enzymatic activity of CBPM and modified the impact of CBPM on bradykinin signaling. We conclude that beneficial properties of Bβ15-42 are not restricted to endothelial cells but are also active in epithelial cells where cytoprotection depends on CBPM binding.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aristolochic Acids
  • Cell Line
  • Fibrin Fibrinogen Degradation Products / pharmacology*
  • Fibrin Fibrinogen Degradation Products / therapeutic use
  • GPI-Linked Proteins / metabolism
  • Humans
  • Kidney Tubules / metabolism
  • Male
  • Metalloendopeptidases / metabolism*
  • Mice, Inbred C57BL
  • Peptide Fragments / pharmacology*
  • Peptide Fragments / therapeutic use
  • Protective Agents / pharmacology*
  • Protective Agents / therapeutic use
  • Protein Binding
  • Receptors, Bradykinin / metabolism
  • Ureteral Obstruction / drug therapy

Substances

  • Aristolochic Acids
  • Fibrin Fibrinogen Degradation Products
  • GPI-Linked Proteins
  • Peptide Fragments
  • Protective Agents
  • Receptors, Bradykinin
  • fibrinogen Bbeta (15-42)
  • aristolochic acid I
  • carboxypeptidase M
  • Metalloendopeptidases